Background: Multidrug-resistant (MDR) tuberculosis (TB) is still a global health threat with close to half a million new cases annually (1). Infection with MDR- or extensively drug resistant (XDR-) TB requires usage of second-line treatment, which is longer, requires costly, more toxic drugs and has a success rate of merely 56% (1). Linezolid is one […]
A Population Pharmacokinetic Model of Linezolid enabling Model-Informed Precision Dosing in Patients with Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis
January 10, 2021
Authors Laurynas Mockeliunas (1), Lina Keutzer (1), Marieke GG Sturkenboom (2), Mathieu S Bolhuis (2), Lotte MG Hulskotte (2), Onno W Akkerman (3,4), Ulrika SH Simonsson (1)
Affiliations 1. Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden, 2. University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands, 3.University of Groningen, University Medical Center Groningen, Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands, 4. University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Groningen, The Netherlands
Presentation type Poster
Presenters Laurynas Mockeliunas
Attachments
